SVR

It started with sunburn. On the windswept beaches of the Baie de Somme on France's northern coast, summer holidaymakers kept walking into a small pharmacy looking for relief, and the pharmacist behind the counter began compounding her own sun product and after-sun soother in the back room. Their effectiveness convinced her husband the kitchen-table experiments deserved a proper laboratory, and a three-generation family enterprise grew out of that seaside demand.

What distinguished the lab from the start was a refusal to pick a side between prescription medicine and cosmetics. It formulated treatments at clinically meaningful active doses while keeping the bases tolerable for reactive skin, building dermo-cosmetics decades before that hyphenated word became a retail category. The catalog still reflects that split personality: an emollient atopic-skin range for the whole family, an anti-redness line for sensitive complexions, a firming range for mature skin, and a high-strength retinol ampoule pairing pure retinol with a stabilized derivative.

The family's grip nearly cost it everything. After heavy investment left the company over-indebted, it slid into French safeguard proceedings in December 2012, a court-supervised bankruptcy protection that could easily have ended the story. Instead, in early 2014, an entrepreneurial investment group and an industry executive who had previously run another French anti-aging house convinced the commercial court, taking a controlling stake while the founding family retained a minority holding. The rescuers poured well over ten million euros into expanding the Essonne-region production site and modernizing R&D, lifting headcount back toward 350.

The relaunch reformulated and redesigned the range while protecting the original high-dose, high-tolerance DNA, and pushed exports aggressively across subsidiaries in Italy, Spain, Belgium, Morocco, and Tunisia plus dozens more markets. The strategy positioned it as one of the last independent French family names still competing among the pharmacy-aisle leaders, trading on transparency about exactly which active sits at which percentage.

Sources:[1][2][3]